Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catheter Precision (VTAK) Research & Development (2017 - 2025)

Catheter Precision (VTAK) has disclosed Research & Development for 9 consecutive years, with $328000.0 as the latest value for Q4 2025.

  • Quarterly Research & Development rose 260.44% to $328000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $862000.0 through Dec 2025, up 216.91% year-over-year, with the annual reading at $862000.0 for FY2025, 216.91% up from the prior year.
  • Research & Development for Q4 2025 was $328000.0 at Catheter Precision, up from $276000.0 in the prior quarter.
  • The five-year high for Research & Development was $3.7 million in Q4 2021, with the low at -$11000.0 in Q4 2023.
  • Average Research & Development over 5 years is $1.0 million, with a median of $197500.0 recorded in 2023.
  • The sharpest move saw Research & Development crashed 107.14% in 2023, then soared 927.27% in 2024.
  • Over 5 years, Research & Development stood at $3.7 million in 2021, then plummeted by 95.87% to $154000.0 in 2022, then plummeted by 107.14% to -$11000.0 in 2023, then skyrocketed by 927.27% to $91000.0 in 2024, then skyrocketed by 260.44% to $328000.0 in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $328000.0, $276000.0, and $155000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.